



Advanced Research of HLA in Diseases

Guest Editor:

**Prof. Dr. Ileana
Constantinescu**

1. Immunology and Transplant
Immunology, Carol Davila
University of Medicine and
Pharmacy, 020021 Bucharest,
Romania

2. Centre of Immunogenetics and
Virology, Fundeni Clinical
Institute, 022328 Bucharest,
Romania

Deadline for manuscript
submissions:

closed (30 April 2024)

Message from the Guest Editor

Recently, scientific research has established strong relationships between specific HLA alleles and different diseases. Early studies focused on the relationship between ankylosing spondylitis and HLA-B*27 underlying the immunogenetic background of this disorder.

Other works have demonstrated connections between HLA genes and autoimmune diseases.

The HLA gene complex has also been positively associated with the risk of infectious disease onset and development like in chronic hepatitis C virus infection: HLA A*23:01, B*44:02, C*04:02.

Other significant associations include examples like chronic renal diseases: B*40, C*12, C*15, and DRB1*14.

Chronic lymphocytic leukemia has been associated with HLA-DRB1*04:02:01 and HLA-DRB3*02:01:01. HLA-B*57:01 is associated with drug hypersensitivity to carbamazepine and abacavir.

This evidence illustrates the significant role of HLA genes in diseases. Further research is needed for a better understanding of the molecular mechanisms underlying these associations with specific HLA molecules.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)